Bacteremia Clinical Trial
— ATTACKOfficial title:
A Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex
Verified date | January 2023 |
Source | Entasis Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a 2-part study, with Part A being the randomized, controlled portion of the study in patients with ABC hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), or bacteremia. Part B is the single-group portion of the study and includes ABC infections that are resistant to or have failed colistin or polymyxin B treatment, as detailed in the inclusion criteria.
Status | Completed |
Enrollment | 207 |
Est. completion date | July 26, 2021 |
Est. primary completion date | July 26, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: PART A 1. A confirmed diagnosis of a serious infection that will require treatment with IV antibiotics; 2. A known infection caused by ABC (bacteremia, HABP, VABP, VP, cUTI or AP, or surgical or post-traumatic wound infections) as either a single pathogen or member of a polymicrobial infection based on evidence from culture or, if available, rapid diagnostic test from a sample collected within 72 hours prior to randomization (HABP/VABP/VP patients), AND 1 of the following: 1. Has received no more than 48 hrs of potentially effective (ie, Gram negative coverage) antimicrobial therapy prior to the first dose of study drug; 2. Is clinically failing prior treatment regimens 3. APACHE II score 10 and 30 inclusive, or SOFA score between 7 and 11 inclusive, at time of diagnosis 4. Expectation, in the judgment of the Investigator, that the patient will benefit from effective antibiotic therapy and appropriate supportive care for the anticipated duration of the study 5. Women of childbearing potential (ie, not post-menopausal or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test before randomization. Participating women of childbearing potential must be willing to consistently use one highly effective method of contraception (ie, condom, combined oral contraceptive, implant, injectable, indwelling intrauterine device, or a vasectomized partner) from Screening until at least 30 days after administration of the last dose of study drug. PART B 1. Has an infection (HABP, VABP, VP, bacteremia, cUTI, AP, or surgical or post-traumatic wound infections) caused by ABC organisms known to be resistant to colistin (defined as MIC =4 mg/L by a non-agar based method); 1. Known to be resistant to colistin or polymyxin B; or 2. Known intolerance to colistin; or 3. Has myasthenia gravis or another neuromuscular syndrome(s) that contraindicates colistin and is not ventilated; or 4. Has acute kidney injury and is receiving renal replacement therapy at study entry. Exclusion Criteria: 1. Evidence of active concurrent pneumonia requiring additional antimicrobial treatment 2. Presence of suspected or confirmed deep seated bacterial infections such as bacterial Gram negative osteomyelitis, endocarditis, or meningitis requiring prolonged therapy, as determined by history and/or physical examination; 3. Sustained shock with persisting hypotension requiring vasopressors to maintain mean arterial pressure (MAP) = 60 mmHg; 4. Pregnant or breastfeeding women; 5. Receiving peritoneal dialysis; 6. Requirement for continuing treatment with probenecid, methotrexate, ganciclovir, valproic acid, or divalproex sodium during the study; 7. Evidence of significant hepatic disease or dysfunction, including known acute viral hepatitis, hepatic cirrhosis, hepatic failure, chronic ascites, or hepatic encephalopathy; |
Country | Name | City | State |
---|---|---|---|
Belarus | Entasis Research Site | Brest | |
Belarus | Entasis Research Site | Gomel | |
Belarus | Entasis Research Site | Grodno | |
Belarus | Entasis Research Site | Minsk | |
Brazil | Entasis Research Site | Belo Horizonte | |
Brazil | Entasis Research Site | Campinas | |
Brazil | Entasis Research Site | Porto Alegre | |
Brazil | Entasis Research Site | Salvador | |
Brazil | Entasis Research Site | Sao Jose do Rio Preto | |
China | Entasis Research Site 1 | Beijing | |
China | Entasis Research Site 2 | Beijing | |
China | Entasis Research Site 3 | Beijing | |
China | Entasis Research Site | Changsha | |
China | Entasis Research Site | Chongqing | |
China | Entasis Research Site | Guangzhou | |
China | Entasis Research Site | Hebei | |
China | Entasis Research Site 1 | Hefei | |
China | Entasis Research Site 2 | Hefei | |
China | Entasis Research Site | Hubei | |
China | Entasis Research Site | Nanchang | |
China | Entasis Research Site | Nanjing | |
China | Entasis Research Site | Nanning | |
China | Entasis Research Site 1 | Shanghai | |
China | Entasis Research Site 2 | Shanghai | |
China | Entasis Research Site | Shenzhen | |
China | Entasis Research Site | Tianjin | |
China | Entasis Research Site | Wuhan | |
Greece | Entasis Research Site 1 | Athens | |
Greece | Entasis Research Site 3 | Athens | |
Greece | Entasis Research Site | Heraklion | |
Greece | Entasis Research Site | Larisa | |
Greece | Entasis Research Site | Larissa | |
Greece | Entasis Research Site | Thessaloniki | |
Hungary | Entasis Research Site 1 | Budapest | |
Hungary | Entasis Research Site 2 | Budapest | |
Hungary | Entasis Research Site | Debrecen | |
India | Entasis Research Site | Ahmedabad | |
India | Entasis Research Site | Belgaum | |
India | Entasis Research Site 1 | Gujrat | |
India | Entasis Research Site 2 | Gujrat | |
India | Entasis Research Site | Hyderabad | |
India | Entasis Research Site | Kolkata | |
India | Entasis Research Site | Pune | |
Israel | Entasis Research Site | Holon | |
Israel | Entasis Research Site | Tel Aviv | |
Israel | Entasis Research Site | Tel Hashomer | |
Israel | Entasis Research Site | Zerifin | |
Korea, Republic of | Entasis Research Site | Gyeonggi-do | |
Korea, Republic of | Entasis Research Site 1 | Seoul | |
Korea, Republic of | Entasis Research Site 2 | Seoul | |
Lithuania | Entasis Research Site | Kaunas | |
Lithuania | Entasis Research Site | Klaipeda | |
Lithuania | Entasis Research Site | Vilnius | |
Mexico | Entasis Research Site 1 | Guadalajara | |
Mexico | Entasis Research Site 2 | Guadalajara | |
Mexico | Entasis Research Site | Mexico DF | |
Mexico | Entasis Research Site | Monterrey | |
Mexico | Entasis Research Site | San Luis Potosi | |
Peru | Entasis Research Site | Bellavista | |
Peru | Entasis Research Site | Cusco | |
Peru | Entasis Research Site | Lima | |
Peru | Entasis Research Site | San Isidro | |
Peru | Entasis Research Site | San Martin de Porres | |
Puerto Rico | Entasis Research Site | Ponce | |
Russian Federation | Entasis Research Site | Arkhangelsk | |
Russian Federation | Entasis Research Site | Krasnodar | |
Russian Federation | Entasis Research Site 1 | Novosibirsk | |
Russian Federation | Entasis Research Site 2 | Novosibirsk | |
Russian Federation | Entasis Research Site 3 | Novosibirsk | |
Russian Federation | Entasis Research Site | Smolensk | |
Russian Federation | Entasis Research Site 2 | St Petersburg | |
Russian Federation | Entasis Research Site 1 | Tomsk | |
Russian Federation | Entasis Research Site 2 | Tomsk | |
Taiwan | Entasis Research Site | Kaohsiung | |
Taiwan | Entasis Research Site | Taichung | |
Taiwan | Entasis Research Site | Taipei | |
Taiwan | Entasis Research Site | Taipei City | |
Thailand | Entasis Research Site | Chiang Mai | |
Thailand | Entasis Research Site | Khon Kaen | |
Thailand | Entasis Research Site | Nakhon Ratchasima | |
Thailand | Entasis Research Site | Nonthaburi | |
Turkey | Entasis Research Site 1 | Ankara | |
Turkey | Entasis Research Site 2 | Ankara | |
Turkey | Entasis Research Site | Eskisehir | |
Turkey | Entasis Research Site | Kocaeli | |
Turkey | Entasis Research Site | Küçükçekmece | |
Turkey | Entasis Research Site | Trabzon | |
United States | Entasis Research Site | Chicago | Illinois |
United States | Entasis Research Site | Cincinnati | Ohio |
United States | Entasis Research Site | Houston | Texas |
United States | Entasis Research Site | Memphis | Tennessee |
United States | Entasis Research Site | Shreveport | Louisiana |
Lead Sponsor | Collaborator |
---|---|
Entasis Therapeutics |
United States, Belarus, Brazil, China, Greece, Hungary, India, Israel, Korea, Republic of, Lithuania, Mexico, Peru, Puerto Rico, Russian Federation, Taiwan, Thailand, Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Patients With All-Cause Mortality in CRABC m-MITT Population | The primary efficacy endpoint for the study is 28-day all-cause mortality in the CRABC m-MITT population in Part A. | 28 Days | |
Primary | Proportion of Patients With Nephrotoxicity | The primary safety endpoint for the study is nephrotoxicity, as measured by the Risk-Injury-Failure-Loss-End-stage renal disease (RIFLE) criteria, in the MITT population in Part A. | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03354338 -
Amoxicillin to Prevent Bacteria and Inflammatory Biomarkers After Intensive Periodontal Therapy
|
Phase 2 | |
Withdrawn |
NCT02543957 -
Factors Associated With Increased Risk of Bacteremia and Cholangitis in ERCP With Cholangioscopy
|
||
Completed |
NCT02210169 -
RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates
|
N/A | |
Completed |
NCT01410578 -
The Value of sTREM-1, PCT, and CRP as Markers for the Detection of Sepsis and Bacteremia Among Patients With a FUO
|
N/A | |
Completed |
NCT00609375 -
Efficacy of Cefepime Continuous Infusion Versus an Intermittent Dosing Regimen
|
Phase 4 | |
Terminated |
NCT00428051 -
Colombia Epidemiologic Surveillance Study
|
N/A | |
Completed |
NCT00177736 -
Pharmacodynamic Parameters of Two Different Doses of Cefepime
|
Phase 4 | |
Terminated |
NCT00108433 -
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
|
Phase 3 | |
Completed |
NCT00571259 -
Prophylactic Antimicrobial Catheter Lock
|
Phase 4 | |
Completed |
NCT00027248 -
Safety and Efficacy of MBI 226 for the Prevention of Central Venous Catheter-Related Bloodstream Infections
|
Phase 3 | |
Completed |
NCT05585463 -
Safety of Acupuncture and Intracutaneous Needles in Pediatric Cancer Patients: a Retrospective Study (ACUSAFE2021)
|
||
Recruiting |
NCT05950984 -
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK)
|
||
Completed |
NCT03148769 -
Spanish Bacteriemia Cohort 2016: Epidemiology, Clinical Management and Prognosis Factors
|
||
Completed |
NCT02536352 -
Effect of Supplementation of Fluoride on Maternal Periodontal Health, Preterm Delivery, and Perinatal Well-Being
|
Early Phase 1 | |
Completed |
NCT02869191 -
Blood Cultures's Profitability in Intensive Care Unit
|
||
Terminated |
NCT01734694 -
Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients
|
Phase 4 | |
Completed |
NCT01179022 -
Incidence of Bacteremia Following Argon Plasma Coagulation in Patients With Endobronchial Lesions
|
N/A | |
Recruiting |
NCT00404625 -
Infections Caused by ESbL-Producing Enterobacteriaceae in Italy
|
N/A | |
Completed |
NCT00398411 -
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
|
Phase 3 | |
Recruiting |
NCT00901602 -
Lebanese Interhospital Pneumococcal Surveillance Program
|